Markers for colorectal cancer

A method for diagnosing or predicting the onset of a cancer in a tissue of an individual, said target protein being from the group of heterogeneous nuclear riboprotein K, high mobility group protein 1 (amphoterin). proteasome subunit alpha type 1, bifunctional purine biosynthesis protein, stress-induced phosphoprotein 1, annexin IV (annexin A4), 60 kDa heat shock protein, T-complex Protein 1, beta subunit, T-complex protein 1, epsilon subunit, mitochondrial stress-70 protein, transitional endoplasmic reticulum ATPase, which method comprises the steps of:

• (a) determining the expression of a target protein of Table 2 in a sample of the tissue from the individual, and
• (b) comparing the pattern or level of expression observed with the pattern or level of expression of the same protein in a second clinically normal tissue sample from the same individual or a second healthy individual, wherein a difference in the expression patterns or levels observed is correlated with the presence of cancer cells in the sample.

(canceled)

A kit for the diagnosis or prognosis of cancer in a sample, which kit comprises:

• (a) a receptacle or other means for receiving a sample to be evaluated, and
• (b) a means for specifically detecting at least one of the presence and y quantity in the sample of a target protein which is from the group of heterogeneous nuclear riboprotein K, high mobility group protein 1 (amphoterin), proteasome subunit alpha type 1, bifunctional purine biosynthesis protein, stress-induced phosphoprotein 1, annexin IV (annexin A4), 60 kDa heat shock protein, T-complex protein 1. beta subunit, T-complex protein 1, epsilon subunit, mitochondrial stress-70 protein, transitional endoplasmic reticulum ATPase, and optionally
• (c) instructions for performing such an assay.

(canceled)

A method of screening for a cancer-therapeutic compound, which method comprises contacting a candidate therapeutic compound with a target protein or a target protein fragment, said target protein being from the group of heterogeneous nuclear riboprotein K, high mobility croup protein 1 (amphoterin), proteasome subunit alpha type 1, bifunctional purine biosynthesis protein, stress-induced phosphoprotein 1, annexin IV (annexin A4), 60 kDa heat shock protein, T-complex protein 1, beta subunit, T-complex protein 1, epsilon subunit, mitochondrial stress-70 protein, transitional endoplasmic reticulum ATPase and assaying (a) for the presence of a complex between the compounds and the target protein or target protein fragment, or (b) for the presence of a complex between the target protein or target protein fragment and a ligand or binding partner thereof.

A method of screening for a cancer-therapeutic compound, which method comprises contacting a candidate therapeutic compound with a target protein or a target protein fragment, said target protein being from the group of heterogeneous nuclear riboprotein K, high mobility group protein 1 (amphoterin), proteasome subunit alpha type 1, bifunctional purine biosynthesis protein, stress-induced phosphoprotein 1, annexin IV (annexin A4), 60 kDa heat shock protein, T-complex protein 1, beta subunit, T-complex protein 1, epsilon subunit, mitochondrial stress-70 protein, transitional endoplasmic reticulum ATPase and assaying the effect of the compound on a biological activity of said target protein or target protein fragment.

-19. (canceled)

A method of screening for a cancer-therapeutic compound, which method comprises:

• (a) providing a cell that over-expresses a target protein or a target protein fragment, said target protein being from the group of heterogeneous nuclear riboprotein K, high mobility group protein 1 (amphoterin), proteasome subunit alpha type 1, bifunctional purine biosynthesis protein, stress-induced phosohoprotein 1, annexin IV (annexin A4), 60 kDa heat shock protein, T-complex protein 1, beta subunit, T-complex protein 1, epsilon subunit, mitochondrial stress-70 protein, transitional endoplasmic reticulum ATPase,
• (b) adding a candidate therapeutic compound to said cell, and
• (c) determining the effect of said compound on the expression or biological activity of said target protein or fragment thereof.

-27. (canceled)

A method for specifically targeting a therapeutic treatment against cancer cells, which method comprises targeting a target protein in the cancer cells, said target protein being from the group of heterogeneous nuclear riboprotein K, high mobility group protein 1 (amphoterin), proteasome subunit alpha type 1, bifunctional purine biosynthesis protein, stress-induced phosphoprotein 1, annexin IV (annexin A4), 60 kDa heat shock protein, T-complex protein 1, beta subunit, T-complex protein 1, epsilon subunit, mitochondrial stress-70 protein, transitional endoplasmic reticulum ATPase.